Drug Abuse Survey, Urine
Detecting drug abuse involving amphetamines, barbiturates, benzodiazepines, cocaine, ethanol, marijuana, opiates, and phencyclidine
This test is an inexpensive urine drugs of abuse screen that can be used when qualitative results are sufficient and when definitive results are not required
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
The test uses immunologic testing to screen for the presence of common drugs of abuse by class. Positive results are not confirmed or quantified by definitive methods. If the results of testing must be definitive, CDAU / Drug Abuse Survey with Confirmation, Urine is recommended.
In some settings (eg, drug treatment programs) screening is used to monitor patients and confirm abstinence.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
The specific drug identified will be reported.
Alcohol: 30 mg/dL
Amphetamines: 500 ng/mL
Barbiturates: 200 ng/mL
Benzodiazepines: 200 ng/mL
Cocaine (benzoylecgonine-cocaine metabolite): 150 ng/mL
Opiates: 300 ng/mL
Phencyclidine: 25 ng/mL
Tetrahydrocannabinol carboxylic acid: 20 ng/mL
The drugs listed above are detected by immunoassay. Positive results should be considered presumptive. Specimens are retained in the laboratory for 2 weeks. Call the laboratory to initiate confirmatory testing if needed. This test is not intended for use in employment-related testing.
A positive result indicates that the patient may have used 1 of the drugs detected by this technique in the recent past (see Cautions about false-positive rate).
The immunoassay methodology used in this test is good for detecting the presence of a drug. However, false-positives do occur (see Cautions).
More detail on each drug group may be found in the specific test designed for that drug (eg, AMPHU / Amphetamines, Urine).
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Not intended for use in employment-related testing.
This technology exhibits a small (approximately 2%) false-positive rate due to interaction of the reagents with naturally occurring substances and over-the-counter drugs. If the results of testing must be absolutely correct, use CDAU / Drug Abuse Survey with Confirmation, Urine.
The test does not screen for drug classes other than those listed above. More comprehensive screening is available using the plasma or urine drug screens (DSS / Drug Screen, Prescription/OTC, Plasma or PDSU / Drug Screen, Prescription/OTC, Urine).
This test is intended to be used only by a qualified drug treatment counselor or physician; results are presumptive only.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
Langman LJ, Bechtel L, Holstege CP: Chapter 35. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Edited by CA Burtis, ER Ashwood, DE Bruns. WB Saunders Company, 2011, pp 1109-1188